KR102703513B1 - 옥사 스파이로 유도체, 이의 제조방법, 및 의약에서 이의 응용 - Google Patents

옥사 스파이로 유도체, 이의 제조방법, 및 의약에서 이의 응용 Download PDF

Info

Publication number
KR102703513B1
KR102703513B1 KR1020187012600A KR20187012600A KR102703513B1 KR 102703513 B1 KR102703513 B1 KR 102703513B1 KR 1020187012600 A KR1020187012600 A KR 1020187012600A KR 20187012600 A KR20187012600 A KR 20187012600A KR 102703513 B1 KR102703513 B1 KR 102703513B1
Authority
KR
South Korea
Prior art keywords
compound
alkyl
formula
group
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187012600A
Other languages
English (en)
Korean (ko)
Other versions
KR20180063251A (ko
Inventor
신 리
빈치앙 펑
양 첸
타오 리우
펑 허
밍순 허
웨이캉 타오
피아오양 순
Original Assignee
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드
샹하이 헨그루이 파마수티컬 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드, 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 filed Critical 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드
Publication of KR20180063251A publication Critical patent/KR20180063251A/ko
Application granted granted Critical
Publication of KR102703513B1 publication Critical patent/KR102703513B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020187012600A 2015-10-15 2016-09-30 옥사 스파이로 유도체, 이의 제조방법, 및 의약에서 이의 응용 Active KR102703513B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201510665328.X 2015-10-15
CN201510665328 2015-10-15
CN201511032876 2015-12-31
CN201511032876.5 2015-12-31
PCT/CN2016/101064 WO2017063509A1 (zh) 2015-10-15 2016-09-30 氧杂螺环类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
KR20180063251A KR20180063251A (ko) 2018-06-11
KR102703513B1 true KR102703513B1 (ko) 2024-09-06

Family

ID=58517778

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187012600A Active KR102703513B1 (ko) 2015-10-15 2016-09-30 옥사 스파이로 유도체, 이의 제조방법, 및 의약에서 이의 응용

Country Status (16)

Country Link
US (1) US10442793B2 (enExample)
EP (1) EP3354649B1 (enExample)
JP (1) JP6824502B2 (enExample)
KR (1) KR102703513B1 (enExample)
CN (1) CN107001347B (enExample)
AU (1) AU2016339404B2 (enExample)
CA (1) CA3000761C (enExample)
DK (1) DK3354649T3 (enExample)
ES (1) ES2772689T3 (enExample)
HU (1) HUE048032T2 (enExample)
MX (1) MX382815B (enExample)
PL (1) PL3354649T3 (enExample)
PT (1) PT3354649T (enExample)
RU (1) RU2733373C2 (enExample)
TW (1) TWI727981B (enExample)
WO (1) WO2017063509A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX388643B (es) * 2017-04-14 2025-03-20 Jiangsu Hengrui Medicine Co Composicion farmaceutica que contiene agonista de mor y agonista de kor, y sus usos
EP3610875B1 (en) * 2017-04-14 2020-10-07 Jiangsu Hengrui Medicine Co., Ltd. Opioid receptor (mor) agonist salt, fumarate salt i crystal form thereof and preparation method thereof
CN108727347B (zh) * 2017-04-14 2020-06-16 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的晶型及其制备方法
CN109206417B (zh) * 2017-07-04 2023-01-03 四川海思科制药有限公司 阿片受体激动剂及其应用
US11072601B2 (en) 2017-09-18 2021-07-27 Shanghai Synergy Pharmaceutical Sciences Co., Ltd. μ-opioid receptor agonist and preparation method therefor and use thereof in field of medicine
WO2019062804A1 (zh) 2017-09-28 2019-04-04 江苏恒瑞医药股份有限公司 一种氧杂螺环类衍生物的制备方法及其中间体
AU2018349930A1 (en) * 2017-10-13 2020-04-16 Shandong Luye Pharmaceutical Co., Ltd. 2,6-dioxaspiro (4,5) decane derivatives and preparation method therefor and pharmaceutical applications thereof
JP2021505547A (ja) * 2017-12-06 2021-02-18 江蘇恒瑞医薬股▲ふん▼有限公司 疼痛を治療するための薬物の製造におけるmorアゴニストと組み合わせたkorアゴニストの使用
CN111836807A (zh) * 2018-04-28 2020-10-27 四川科伦博泰生物医药股份有限公司 氧杂螺环类化合物及其制备方法和用途
CN108424372B (zh) * 2018-05-11 2021-08-10 浙江华贝药业有限责任公司 2,2,2-三氟-n-[(s)-4-羰基四氢萘-1-基]-乙酰胺的纯化工艺
CN111163778B (zh) * 2018-05-14 2023-01-24 江苏恒瑞医药股份有限公司 一种mor受体激动剂药物组合物
CN108707086B (zh) * 2018-05-15 2021-08-10 浙江华贝药业有限责任公司 一种(1s,4s)-n-(4-羟基四氢萘-1-基)叔丁氧基碳酰胺的纯化工艺
WO2020073985A1 (zh) * 2018-10-12 2020-04-16 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
WO2020073984A1 (zh) * 2018-10-12 2020-04-16 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
CN112334465B (zh) * 2019-01-17 2024-06-11 上海海雁医药科技有限公司 三环取代的氧杂螺环衍生物、其制法与医药上的用途
CN111662284B (zh) * 2019-03-06 2021-08-10 上海海雁医药科技有限公司 双杂环取代的氧杂螺环衍生物、其制法与医药上的用途
WO2021027304A1 (zh) * 2019-08-14 2021-02-18 上海海雁医药科技有限公司 镇痛化合物、其制法与医药上的用途
EP4092031A4 (en) * 2020-01-17 2024-02-21 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. AZABICYCLIC SUBSTITUTED OXASPIRO DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF AND ITS MEDICAL USE
CN118221680A (zh) 2020-01-17 2024-06-21 上海海雁医药科技有限公司 光学纯的氧杂螺环取代的吡咯并吡唑衍生物、其制法与医药上的用途
CN113214264B (zh) * 2020-01-21 2022-08-09 上海海雁医药科技有限公司 二氢吡咯并五元杂芳基取代的氧杂螺环衍生物、其制法与医药上的用途
JP7781064B2 (ja) 2020-01-22 2025-12-05 江蘇恒瑞医薬股▲ふん▼有限公司 抗trop-2抗体-エキサテカン類似体複合体及びその医薬用途
CN114075141B (zh) * 2020-08-20 2025-02-25 上海致根医药科技有限公司 阿片受体“偏向性”配体、其制备方法及其在医药上的应用
CN114539257B (zh) * 2020-11-24 2023-08-11 江苏恒瑞医药股份有限公司 嘧啶二酮类螺环衍生物、其制备方法及其在医药上的应用
JP7751645B2 (ja) 2020-12-29 2025-10-08 上海海雁医薬科技有限公司 オキシスピロ環置換ピロロピラゾール誘導体及びその中間体並びにその調製方法
WO2023284788A1 (zh) 2021-07-13 2023-01-19 上海海雁医药科技有限公司 Mor受体激动剂的药学上可接受的盐、其多晶型物及其用途
WO2023011422A1 (zh) * 2021-08-02 2023-02-09 上海枢境生物科技有限公司 氧杂螺环类衍生物、制备方法及其用途
CN117263956A (zh) * 2022-01-19 2023-12-22 天地恒一制药股份有限公司 阿片受体激动剂及其制备方法和用途
CN116589451B (zh) * 2022-02-11 2024-07-09 成都硕德药业有限公司 一种6-氧杂螺[4,5]癸烷类化合物的新晶型、用途及其制备方法
CN117624138A (zh) * 2022-08-29 2024-03-01 江苏恒瑞医药股份有限公司 一种氧杂螺环类衍生物的可药用盐、晶型及制备方法
CN119894904B (zh) * 2022-09-27 2025-12-30 上海枢境生物科技有限公司 一种含螺环类衍生物的盐、晶型及其制备方法和应用
KR20250137614A (ko) 2023-01-18 2025-09-18 상하이 센후이 메디슨 컴퍼니 리미티드 테트라히드로-1-나프틸아민 및 이의 유도체의 제조 방법
WO2026026772A1 (zh) * 2024-07-30 2026-02-05 上海枢境生物科技有限公司 氧杂螺环类衍生物的富马酸盐晶型及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103702561A (zh) 2011-03-23 2014-04-02 特维娜有限公司 阿片样物质受体配体以及使用和制备其的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2160534B1 (es) 1999-12-30 2002-04-16 Vita Invest Sa Nuevos esteres derivados de (rr,ss)-2-hidroxibenzoato de 3-(2-dimetilaminometil-1-hidroxiciclohexil) fenilo.
DE10044649A1 (de) 2000-09-08 2002-07-04 Gruenenthal Gmbh Substituierte 4-Phenyl-1-(1-phenyl-cyclohexyl)-1,2,3,6-tetrahydropyridine
DE102006033109A1 (de) * 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
US7999107B2 (en) * 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
US20090028873A1 (en) 2007-07-27 2009-01-29 Auspex Pharmaceuticals, Inc. Substituted cyclohexanols
AU2009308769B2 (en) 2008-10-31 2015-03-12 Pain Therapeutics, Inc. Filamin A-binding anti-inflammatory analgesic
CN102741258B (zh) 2009-06-17 2015-09-30 德州大学体系董事会 作为分离剂的环果聚糖的组成物及方法
CN104159902B (zh) 2011-12-12 2016-05-04 格吕伦塔尔有限公司 制备(1r,4r)-6’-氟-(N,N-二甲基-和N-甲基)-4-苯基-4’,9’-二氢-3’H-螺[环己烷-1,1’-吡喃并[3,4,b]吲哚]-4-胺的方法
PL2880037T3 (pl) 2012-08-03 2019-07-31 Johnson Matthey Public Limited Company Sposób wytwarzania oksykodonu
RS55593B1 (sr) 2012-11-13 2017-06-30 Array Biopharma Inc Jedinjenja biciklične uree, tiouree, guanidina i cijanoguanidina korisna za lečenje bola

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103702561A (zh) 2011-03-23 2014-04-02 特维娜有限公司 阿片样物质受体配体以及使用和制备其的方法

Also Published As

Publication number Publication date
TWI727981B (zh) 2021-05-21
CN107001347B (zh) 2019-09-24
RU2018115569A (ru) 2019-11-18
HUE048032T2 (hu) 2020-05-28
AU2016339404A1 (en) 2018-05-24
US10442793B2 (en) 2019-10-15
TW201718558A (zh) 2017-06-01
CA3000761C (en) 2024-02-13
JP6824502B2 (ja) 2021-02-03
AU2016339404B2 (en) 2020-08-27
DK3354649T3 (da) 2020-02-24
US20180297988A1 (en) 2018-10-18
RU2018115569A3 (enExample) 2020-01-20
WO2017063509A1 (zh) 2017-04-20
CA3000761A1 (en) 2017-04-20
MX382815B (es) 2025-03-12
EP3354649B1 (en) 2019-12-04
RU2733373C2 (ru) 2020-10-01
EP3354649A1 (en) 2018-08-01
BR112018006448A2 (pt) 2018-10-16
JP2018534257A (ja) 2018-11-22
PT3354649T (pt) 2020-02-03
EP3354649A4 (en) 2018-08-08
ES2772689T3 (es) 2020-07-08
PL3354649T3 (pl) 2020-07-27
CN107001347A (zh) 2017-08-01
MX2018004175A (es) 2018-06-06
KR20180063251A (ko) 2018-06-11

Similar Documents

Publication Publication Date Title
KR102703513B1 (ko) 옥사 스파이로 유도체, 이의 제조방법, 및 의약에서 이의 응용
JP7813970B2 (ja) 縮合イミダゾール誘導体、その調製方法及びその医薬的応用
EP3087080B1 (en) Cortistatin analogues and syntheses and uses thereof
MX2010010494A (es) Derivados espirociclicos como inhibidores de la histona-desacetilasa.
CA2764653A1 (en) Tetracyclic compounds
JP7781059B2 (ja) ピラゾロヘテロアリール系誘導体、その調製方法及びその医薬的応用
TW202003495A (zh) 苯並哌啶或雜芳基並哌啶類衍生物、其製備方法及其在醫藥上的應用
KR20230164093A (ko) 테트라하이드로나프탈렌 화합물, 이를 위한 제조 방법 및 의약에서 이의 용도
KR20220125272A (ko) 트리사이클릭 테트라하이드로이소퀴놀린 유도체, 이를 제조하기 위한 방법 및 의료분야에서 이의 용도
CA3143367A1 (en) Indazole derivative, preparation method therefor, and pharmaceutical application thereof
DE60201447T2 (de) Antidepressive azaheterocyclylmethylderivate von 7,8-dihydro-1,6,9-trioxa-3-azacyclopenta(a)naphthalin
CN112996783A (zh) 2-氨基嘧啶类衍生物、其制备方法及其在医药上的应用
WO2023046214A1 (zh) 一种受体相互作用蛋白激酶1的抑制剂及其制备方法、应用
TW202321258A (zh) 氧雜螺環類衍生物、製備方法及其用途
BR112018006448B1 (pt) Derivado de oxaespiro, seu uso e processo de preparação, e composição farmacêutica
HK1238242B (zh) 氧杂螺环类衍生物、其制备方法及其在医药上的应用
RU2830109C1 (ru) Трициклическое тетрагидроизохинолиновое производное, способ его получения и его применение в медицине
CN111285825B (zh) 一类苯磺酰胺取代的衍生物,其制法及其用途
HK1238242A1 (en) Oxa spiro derivative, preparation method therefor, and applications thereof in medicines
HK40076301A (en) Tricyclic tetrahydroisoquinoline derivative, preparation method therefor and application thereof in medicine
EA048455B1 (ru) СОЕДИНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА КИНАЗЫ Akt
HK40064838A (en) Indazole derivative, preparation method therefor, and pharmaceutical application thereof
NZ793890A (en) Substituted pyridinone-containing tricyclic compounds, and methods using same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180502

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210831

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231107

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240715

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240902

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240903

End annual number: 3

Start annual number: 1

PG1601 Publication of registration